Search company, investor...

Nitec Pharma

Founded Year



Merger | Merged

About Nitec Pharma

Nitec Pharma is a specialty pharmaceutical company focused on the development and commercialization of medicines and effective treatment solutions for chronic inflammation and pain-related diseases. The Company seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets.In April 2012, Nitec Pharma merged with Horizon Therapeutics. The valuation of Nitec Pharma was undisclosed. Other terms of the deal were not released. The combined company will be named Horizon Pharma, Inc.

Headquarters Location

Roschenzerstrasse 9



Missing: Nitec Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nitec Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Nitec Pharma Frequently Asked Questions (FAQ)

  • When was Nitec Pharma founded?

    Nitec Pharma was founded in 2004.

  • What is Nitec Pharma's latest funding round?

    Nitec Pharma's latest funding round is Merger.

  • Who are the investors of Nitec Pharma?

    Investors of Nitec Pharma include Horizon Therapeutics, Atlas Venture, NGN Capital and Global Life Science Ventures.

  • Who are Nitec Pharma's competitors?

    Competitors of Nitec Pharma include Alpex Pharma, Aquinox Pharmaceuticals, Eyegate Pharmaceuticals, Curetis, Soleno Therapeutics, Presidio Pharmaceuticals, aTyr Pharma, Auxilium Pharmaceuticals, NuPathe, Acton Pharmaceuticals and 34 more.

Compare Nitec Pharma to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.


Xigen develops therapeutic peptides for a range of diseases.

ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.

Naxospharma srl

greece vacation pharmaceutical company athens hotel naxos pharma travel tour

Azur Pharma Logo
Azur Pharma

Azur Pharma is a pharmaceutical company focused on the CNS, women's health and urology markets of the US.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.